Adaptimmune Therapeutics Stock (NASDAQ: ADAP)

Adaptimmune Therapeutics

Adaptimmune Therapeutics PLC is a clinical-stage biopharmaceutical company. It focused on providing novel cell therapies to patients, particularly in solid tumors. It has developed a comprehensive proprietary platform that enables it to identify cancer targets, find and genetically engineer T-cell receptors, and produce TCR therapeutic candidates for administration to patients. Its programs include MAGE-A4 SPEAR T-cell therapy, NY-ESO SPEAR T-cell, CD70 and others for multiple cancer types.

movers image

News

Pre-Market Outlook

Markets

Movers

Trading Ideas

ADAP

AILE

AIMD

ANTE

CMAX

ESPR

MASSIVE INTERACTIVE NV by Massive Interactive, Inc.

HUGE

HUMA

LGMK

MMAT

NDRA

PSIG

SNOA

TNON

YMAB

Why Ainos Shares Are Trading Higher By Around 38%; Here Are 20 Stocks Moving Premarket

Biotech

Health Care

General

GLPG

FDA approves Adaptimmune Therapeutics&#39; Tecelra for unresectable or metastatic synovial sarcoma, a rare cancer near large joints. Tecelra, the first engineered cell therapy for solid tumors in the U.S., showed a 43% ORR and a median response duration of six months.

FDA Approves Adaptimmune Therapeutics&#39; Engineered Cell Therapy As First For Solid Tumor And New Therapy For Rare Soft Tissue Cancer In Over A Decade

Penny Stocks

By Michael Kim

READ THE FULL ADAP RESEARCH REPORT

ADAP: Initiating Coverage of Adaptimmune, a Leading T-Cell Therapy Company

Adaptimmune Therapeutics plc - American Depositary Shares

Adaptimmune Therapeutics PLC

ADAPad

Adappter Token

AdaptHealth Corp

ADAPTIVE AD SYSTEMS INC by Adaptive Ad Systems, Inc.

Adaptive Ad Systems Inc

Adaptive Alpha Opportunities ETF

Adaptive Biotechnologies Corporation - Common Stock

Adaptive Biotechnologies Corp

Adaptive Core ETF

Adaptive Hedged Multi-Asset Income ETF

Press Releases

Adaptimmune Reports Q2 2024 Financial and Business Updates

Adaptimmune to Participate in Two Bank Conferences this September

Adaptimmune to Report Q3 2024 Financial and Business Updates on Wednesday, November 13, 2024

Adaptimmune to Participate in Scientific and Medical Conferences this November and December

Adaptimmune's Lete-cel Achieves Primary Endpoint in Pivotal Trial

Adaptimmune Reports Q3 2024 Financial and Business Updates

First Patient Treated with Adaptimmune's TECELRA(R) (afamitresgene autoleucel)

Adaptimmune Announces Changes to its Executive Leadership Team Based in The UK

Adaptimmune Announces U.S. FDA Breakthrough Therapy Designation Granted to Letetresgene Autoleucel (lete-cel) for Treatment of Myxoid/Round Cell Liposarcoma (MRCLS)

Adaptimmune to Participate in the Guggenheim Securities SMID Cap Biotech Conference February 6, 2025

AFFX

CAMP4 Therapeutics Corporation - Common Stock

Camp4 Therapeutics

Coherus BioSciences

Cellectis S.A. - American Depositary Shares

Cellectis

Coya Therapeutics

Editas Medicine

Elicio Therapeutics

Elutia

Fate Therapeutics

Galectin Therapeutics Inc. - Common Stock

Galectin Therapeutics

Genelux

Invivyd

Kyverna Therapeutics, Inc. - Common Stock

Kyverna Therapeutics

Lineage Cell Therapeutics, Inc. Common Stock

Lineage Cell Therapeutics

Lexicon Pharmaceuticals, Inc. - Common Stock

Lexicon Pharmaceuticals

Seres Therapeutics

Nkarta

OncoCyte

ProKidney Corp. - Class A Ordinary Shares

ProKidney

Sagimet Biosciences Inc. - Series A Common Stock

Sagimet Biosciences

Sutro Biopharma

TScan Therapeutics

Instil Bio

Vor Biopharma

Vaxart

Zentalis Pharmaceuticals, Inc. - common stock

Zentalis Pharma

Mizuho

HC Wainwright & Co.

Guggenheim

Scotiabank

EF Hutton

Adaptive Brdbnd

Comments

Adaptimmune Therapeutics

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga